Publications by authors named "Gilbert X Gonzalez"
Article Synopsis
- mRNA vaccines have shown effectiveness and safety in preventing infectious diseases, prompting the development of a novel multivalent influenza vaccine using lipid nanoparticles (LNPs) encoding various viral proteins.
- Immunization with these mRNA LNPs led to strong immune responses, promoting both cellular immunity and high levels of specific antibodies in mice, especially when cGAMP was used as an adjuvant.
- The addition of cGAMP resulted in significantly enhanced immune responses, including increased secretion of important cytokines and a greater presence of memory T cells in both the spleen and lungs, ultimately providing strong protection against different strains of the virus.
Article Synopsis
- Influenza epidemics, especially type B, pose a major public health risk, with current vaccines showing limited effectiveness due to changes in virus strains.
- Researchers developed double-layered protein nanoparticles using structure-stabilized HA stalk antigens from influenza B, which were found to activate immune cells effectively.
- Immunization with these nanoparticles led to strong and lasting immune responses, suggesting their potential as a universal vaccine with enhanced protection against various influenza B virus strains.
Article Synopsis
- SARS-CoV-2, responsible for the global pandemic, is evolving with new variants, and existing vaccines focusing on the prefusion spike protein (Pre) show limited effectiveness against these variants.
- Research indicates that while Pre can elicit strong neutralization responses, the stem subunit (S2) of the spike protein produces more balanced IgG antibodies and better antibody-dependent cellular cytotoxicity (ADCC) activity.
- By combining Pre and S2 into double-layered protein nanoparticles, the study finds that these nanoparticles enhance both neutralizing antibodies and ADCC activity, leading to improved and sustained immune responses, suggesting their potential for developing safer and broader SARS-CoV-2 vaccines.
Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice.
ACS Appl Mater Interfaces
February 2022
The intranasal (i.n.) route is an ideal vaccination approach for infectious respiratory diseases like influenza.
View Article and Find Full Text PDFInfluenza viral infection causes acute upper respiratory diseases in humans, posing severe risks to global public health. However, current vaccines provide limited protection against mismatched circulating influenza A viruses. Here, the immune responses induced in mice by novel double-layered protein nanoparticles were investigated.
View Article and Find Full Text PDFIntranasal (i.n.) immunization is a promising vaccination route for infectious respiratory diseases such as influenza.
View Article and Find Full Text PDFArticle Synopsis
- The pursuit of a universal influenza vaccine aims to reduce public health risks from influenza outbreaks, but progress has been hindered by the limited immune response elicited by conserved viral components.
- Layered protein nanoparticles that incorporate stabilized structures of influenza proteins have shown enhanced immunogenicity, allowing for improved immune responses in experimental models.
- Specifically, double-layered protein nanoparticles featuring M2e and neuraminidase have demonstrated strong and lasting immune protection, indicating their potential as a foundation for universal influenza vaccines and a versatile platform for other vaccines as well.
Current influenza vaccines provide limited protection against circulating influenza A viruses. A universal influenza vaccine will eliminate the intrinsic limitations of the seasonal flu vaccines. Here we report methodology to generate double-layered protein nanoparticles as a universal influenza vaccine.
View Article and Find Full Text PDFThe biodegradable microneedle patch (MNP) is a novel technology for vaccine delivery that could improve the immunogenicity of vaccines. To broaden the protective efficiency of conventional influenza vaccines, a new 4M2e-tFliC fusion protein construct containing M2e sequences from different subtypes was generated. Purified fusion protein was encapsulate into MNPs with a biocompatible polymer for use as a boosting vaccine.
View Article and Find Full Text PDF